Gilead to launch authorized generics of two HCV drugs: The goal is to remain competitive while lowering the cost for patients
From the article:
The effect on costs for patients and overall spending remains to be seen. “It’s unlikely this will result in lower government spending because this is what governments were approximately paying already,” says Rachel Sachs, a professor and innovation policy expert at Washington University School of Law.
Although Medicaid patients, who have little or no cost sharing with their insurer, will not see a difference at the pharmacy, people with Medicare Part D, who have high cost-sharing, could see their out-of-pocket costs go down—Gilead believes by as much as $2,500 per patient.health law policy pharmaceuticals rachel sachs regulation